The Company expects to report topline data from the trial in December 2024 ... as compared to $74.6 million for the same period in 2023. The decreases were primarily a result of reduced clinical ...
Goldman Sachs analyst Louise Singlehurst maintained a Buy rating on EssilorLuxottica SA (0OMK – Research Report) today and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback